Hemmorex-HC

Manufacturer
Laser Pharmaceuticals, LLC
Effective date
2026-01-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
monthly-update
Hydrated at
2026-06-03 17:54:05

Label at a glance#

ProductHemmorex-HC
Active ingredientHYDROCORTISONE ACETATE
Label structure14 sections

Indications and uses

Hemmorex-HC™ suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

Dosage and administration

For rectal administration. Detach one suppository from strip of suppositories. Remove the wrapper. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository thre...

Storage and handling

Store at 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature]. Excursions permitted to 15º-30ºC (59º-86ºF). Store away from heat. Protect from freezing. Manufactured for: Laser Pharmaceuticals, LLC 1015 Nine North Drive, Ste 400 Alpharetta, GA 30004 770-754-9846 Rev. 04/20

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

HEMMOREX-HC™

(hydrocortisone acetate suppositories), 30 mg

Rx Only

For Rectal Administration

DESCRIPTION:

DESCRIPTION SECTION

Hydrocortisone acetate is a corticosteroid designed chemically as pregn-4-ene 3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy––(11 β) with the following structural formula:

structural formulastructural formula

Each rectal suppository contains hydrocortisone acetate, USP 30 mg in a specially blended hydrogenated vegetable oil base.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Hemmorex-HC™ suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Hemmorex-HC™ suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

PRECAUTIONS:

PRECAUTIONS SECTION

Do not use Hemmorex-HC™ suppositories unless adequate proctologic examination is made. If irritation develops, the product should be discontinued and appropriate therapy instituted. In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Hemmorex-HC™ should be discontinued until the infection has been adequately controlled.

Carcinogenesis:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Pregnancy Category C:

PREGNANCY SECTION

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women. Hemmorex-HC™ suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Hemmorex-HC™ suppositories, a decision should be

made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported with corticosteroid suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

DRUG ABUSE AND DEPENDENCE:

DRUG ABUSE AND DEPENDENCE SECTION

Drug abuse and dependence have not been reported in patients treated with Hemmorex-HC™ suppositories.

OVERDOSAGE:

OVERDOSAGE SECTION

If signs and symptoms of systemic overdosage occur, discontinue use.

WARNING

WARNINGS SECTION

Keep this and all drugs out of the reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

For rectal administration. Detach one suppository from strip of suppositories. Remove the wrapper. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

All prescription substitutions and/or recommendations using this product shall be made subject to state and federal statutes as applicable. Please NOTE: This is not an Orange Book product and has not been subjec ted to FDA therapeutic or other equivalency testin g. No representation is made as to generic status or bioequivalency . Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information provided herein.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Hemmorex-HC™ (hydrocortisone acetate suppositories), 30 mg are off-white, smooth surfaced and bullet shaped with one pointed end.

Box of 12 suppositories, NDC 16477-202-12.

STORAGE:

STORAGE AND HANDLING SECTION

Store at 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature]. Excursions permitted to 15º-30ºC (59º-86ºF). Store away from heat. Protect from freezing.

Manufactured for:
Laser Pharmaceuticals, LLC

1015 Nine North Drive, Ste 400

Alpharetta, GA 30004

770-754-9846

Rev. 04/20

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

labellabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1674200HEMMOREX-HC 30 MG Rectal SuppositoryPSN4
1291085hydrocortisone acetate 30 MG Rectal SuppositoryPSN4
1674200hydrocortisone acetate 30 MG Rectal Suppository [Hemmorex]SBD4
1291085hydrocortisone acetate 30 MG Rectal SuppositorySCD4
1674200Hemmorex 30 MG Rectal SuppositorySY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
HYDROCORTISONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
15bd4439-874a-4934-9954-248e5455d460Product name120260310
9962b773-9f2e-22cc-0032-535e48ac417bProduct name320250724
56bb0587-1bf2-48b2-9d93-fc9f59d1eeb2Product name120250325
4d56e8eb-d741-d4a5-de3f-2bab1af75a60Product name720220608
626d7260-31b5-4412-84fd-579746adb6b3Product name120210513
8a011600-5e61-4c59-ab7b-54ab658a3b71Product name220181127
a919621a-248d-3c7a-1084-9f9ce286fdfdProduct name220181009
e7d5a174-836b-a0af-b014-cb0826c69ddcProduct name220181004
fcce390d-6460-4701-87cf-940d8800a1c3Product name220180212
bf065fa6-1e3b-e4c3-0bde-2dc842ceeea1Product name220150218
02657a3f-1489-66ea-f740-5ab9524e57d7Product name120140508
26f3d783-2cc1-4327-e77d-71804cf675a2Product name120140508
36fdc54c-bbeb-981e-8a53-4d768e283892Product name120140508
58f3f9b7-3b9b-a9c1-1c9f-18ac777192b8Product name120140508
61e59a42-186b-9f4b-aec3-fb49a6debc31Product name120140508
705740e1-dee5-2610-c5a3-4c59cd9d62afProduct name120140508
7bdc4804-3832-c0df-e519-72b6d47c9792Product name120140508
a7051cba-790b-a699-81f8-dbbbdbd9b5acProduct name120140508
abaf203f-619e-f265-559f-8c81af5cb1c2Product name120140508
acc4d8bb-0e29-e9f8-65f8-31e94184a9c0Product name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
bfd28ffb-d550-3fe9-f65b-10bcb7f971fdProduct name120140508
da108d9e-edc8-17a3-8c28-3251c6a8acccProduct name120140508
fe21f3fd-a378-0654-1972-db3c3b64470eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
16477-202-12Hemmorex-HC12 in 1 BOXSUPPOSITORY124

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
16477-202-12EA - Each16477-20209df2b6a-5271-4903-9546-7bf4ee9aaf6a12015-11-12

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
HYDROCORTISONE ACETATEACTIVE INGREDIENT3X7931PO741
HYDROCORTISONEACTIVE MOIETYWI4X0X7BPJ1
HYDROGENATED COCO-GLYCERIDESINACTIVE INGREDIENTXDD37N2GPR1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
16477-20216477-202-12

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
32021-08-05full-release2026-05-31 20:37:30

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Hemmorex-HCHYDROCORTISONE ACETATELaser Pharmaceuticals, LLCd625764a-6171-4802-9bc0-95e5785b8b7d2026-01-01Warnings, Adverse reactionsExact identifier
ndc (package): 16477-202-12
ndc (product): 16477-202
ndc11 (package): 16477020212
spl id: 47d761e2-d5ae-52a0-e063-6394a90a94e1
spl set id: d625764a-6171-4802-9bc0-95e5785b8b7d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.